Industry trends_News information_Beijing Dongfang Baitai Biotechnology Co., Ltd|Malignant tumor|diabetes mellitus|autoimmune diseases

Welcome to: Beijing Dongfang Baitai Biotechnology Co., Ltd



Home
About 
-  About
- Company Profile
- Corporate culture
- development history
- Organizational structure
- Leadership care
- Enterprise honor
Gather innovative strength to meet patients' drug needs
Beijing Dongfang Baitai Biotechnology Co., Ltd. is a high-tech enterprise committed to the R&D and production of innovative biological drugs
See more +
R&D Technology 
-  R&D Technology
- Technology platform
- R&D achievements
- Quality and production
Professional and concentrated research and development of enabling drugs
Collision of ingenuity and wisdom, gathering of high-level scientific research talents, contributing to drug innovation
See more +
Product 
-  Product
- R&D pipeline
- Clinical recruitment
Innovation drives quality first
Quality is the lifeblood of drug research and development. We should uphold integrity and innovation, strictly control the quality, and ensure the healthy life of human beings
See more +
News 
-  News
- Company News
- Industry trends
Explore cutting-edge technologies and track the latest trends
Grasp the new trend of the industry and analyze the new trend of drug research and development
See more +
Join us 
-  Join us
- Social recruitment
- Campus recruitment
- Postdoctoral workstation
Win win cooperation before going to work
From innovation to manufacturing, help everyone achieve success and join hands in the blue ocean of drug research and development
See more +
Contact 
-  Contact
- Cooperation opportunities
- Online Message
Innovation drives development, and cooperation achieves win-win results
Adhere to innovation, master the core technology of pharmacy, opportunities and challenges coexist, and the transformation of biological drugs starts from now on
See more +

News trends

Position：

Homepage

News information

Industry trends

Check category 



Company News

Industry trends

行業動态 Industry dynamic

05-20 

2021中國(guó)生(shēng)物醫藥行業十大(dà)熱(rè)點事(shì)件(jiàn)

2021年(nián)，生(shēng)物醫藥領域迎來(lái)了多項裡(lǐ)程碑事(shì)件(jiàn)，國(guó)家指導扶持的相(xiàng)應政策相(xiàng)繼出台，新冠疫苗、特效藥物陸續研發上市，兩款CAR-T相(xiàng)繼獲批開創國(guó)内細胞療法元年(nián)，國(guó)内首個“現貨型”CAR-NK獲批臨床。

05-20 

疫情時代下的生(shēng)物技術(shù)投融資上漲

2021年(nián)，在公開市場上，生(shēng)物技術(shù)的投資高居榜首。近三年(nián)來(lái)受到新冠疫情全球大(dà)流行的影(yǐng)響，生(shēng)物醫藥行業持續受到資本市場的矚目。中國(guó)作(zuò)爲全球醫藥行業發展的重要力量和全球應對新冠疫情最好的國(guó)家之一，适應了新冠疫情帶來(lái)的變化和沖擊。雖然生(shēng)物醫藥行業投融資規模出現了一定的周期波動，但(dàn)是整體(tǐ)呈螺旋上升趨勢。

05-20 

中國(guó)藥物研發正進入創新新時代

科(kē)技進步，再加上政府激勵和監管改革，近年(nián)來(lái)中國(guó)新藥研發勢頭發展強勁，可(kě)以說(shuō)中國(guó)新藥已經進入充滿活力和創新的新時代。

05-20 

中國(guó)創新藥發展迅猛，同靶點影(yǐng)響試驗效率

中國(guó)的監管改革促進了本土(tǔ)醫療創新。獲批IND和獲批NDA數量的趨勢以及這些批準所花費的時間表明，這些變更的影(yǐng)響通常是有益的。盡管如(rú)此，具有相(xiàng)同靶點的多個産品的聚集和低效的臨床試驗過程将影(yǐng)響真正有意義的創新藥物從(cóng)IND到NDA批準的進程。